- Obama not worried about Ebola at upcoming African summit in D.C.
- Obama: ‘We tortured some folks’ after 9/11
- Obama administration asked whole D.C. Circuit to take on major Obamacare case
- Mark Levin: Topple GOP leadership or country will ‘unravel’
- Massachusetts to let police chief deny gun buys to those deemed unfit
- John Kerry condemns attack on Israeli soldiers, kidnapping
- U.S. starts to evacuate American Ebola patients from West Africa: Report
- Geraldo slammed as ‘dummy’ for backing Clinton’s bin Laden claim
- Israeli spokesman: No need to debate who broke the cease-fire
- 35 Palestinians killed; Israeli officer missing
By Orrin G. Hatch
Procedural changes impede the chamber's traditional deliberative function
Topic - Schering-Plough Corp.
Drugmaker Merck & Co. said Thursday it lost $531 million in the fourth quarter due to nearly $4 billion charges, including writeoffs and restructuring costs from its acquisition of Schering-Plough Corp. in 2009.
Drugmaker Merck & Co. said Thursday it doesn't expect arbitrators to rule until sometime next year on its multi-billion-dollar dispute with Johnson & Johnson over rights to two lucrative drugs for immune disorders.
Drugmaker Merck & Co. plans to appeal a federal court verdict that a former subsidiary caused the commonwealth of Massachusetts to overpay pharmacists for a widely used asthma medication, the company said Thursday.
Drugmaker Merck & Co. said Tuesday that arbitration will begin in late September in its dispute with Johnson & Johnson over revenue from two blockbuster drugs for rheumatoid arthritis and other immune disorders.